We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
- Authors
Jagannath, Sundar; Rifkin, Robert M.; Gasparetto, Cristina J.; Toomey, Kathleen; Durie, Brian G.M.; Hardin, James W.; Terebelo, Howard R.; Wagner, Lynne; Narang, Mohit; Ailawadhi, Sikander; Omel, James L.; Srinivasan, Shankar; He, Mia; Ung, Brian; Kitali, Amani; Flick, E. Dawn; Agarwal, Amit; Abonour, Rafat; CONNECT MM Registry Investigators
- Abstract
Sankey plots were generated to illustrate the heterogeneity of treatment sequences and transitions over time in real-world patients from the Connect Multiple Myeloma (MM) Registry. Plots identified immunomodulatory agents and proteasome inhibitors as the mainstays of treatment for patients who did or did not receive stem cell transplant. More patients received stem cell transplant (shown above) and continued to second-line treatment, which highlights the need to choose optimal first-line regimens – particularly for patients without a transplant intent. Abbreviations: IMiD = Immunomodulatory imide; 1L = first-line; 3L = third-line; PFS = progression-free survival; PI = proteasome inhibitor; SCT = stem cell transplant.
- Subjects
STEM cell transplantation; MULTIPLE myeloma treatment; MULTIPLE myeloma diagnosis; SURVIVAL; RESEARCH; PROTEASE inhibitors; HOMOGRAFTS; RESEARCH methodology; ACQUISITION of data; PROGNOSIS; MEDICAL cooperation; EVALUATION research; COMPARATIVE studies; IMMUNOLOGICAL adjuvants; MULTIPLE myeloma
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2020, Vol 20, Issue 5, p272
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2019.10.002